Jubilant Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Jubilant Therapeutics's estimated annual revenue is currently $2.6M per year.
- Jubilant Therapeutics's estimated revenue per employee is $219,583
Employee Data
- Jubilant Therapeutics has 12 Employees.
- Jubilant Therapeutics grew their employee count by -14% last year.
Jubilant Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Sr. Director, Business Development | Reveal Email/Phone |
Jubilant Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $8.5M | 46 | 2% | N/A | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $8.5M | 30 | -33% | N/A | N/A |
#4 | $108.5M | 434 | 6% | N/A | N/A |
#5 | $0.8M | 4 | 0% | N/A | N/A |
#6 | $0.6M | 3 | 0% | N/A | N/A |
#7 | $14.7M | 68 | -23% | $206.4M | N/A |
#8 | $492.2M | 1503 | -15% | $568M | N/A |
#9 | $1.1M | 10 | 67% | N/A | N/A |
#10 | $4.5M | 25 | 4% | N/A | N/A |
What Is Jubilant Therapeutics?
Jubilant Therapeutics is a patient-focused biopharmaceutical company advancing potent and selective small molecule modulators to address specific unmet medical needs in oncology and autoimmune diseases. The company’s leadership and scientific team are science-driven executives with global pharma background and experience in advancing innovative drug candidates into the clinic. Jubilant Therapeutics is headquartered in the U.S. with independent board and management, guided by globally renowned KOLs and SAB. Key Therapeutic Areas • Oncology • Auto-immune Disorders Portfolio • Novel PAD4 inhibitors targeting auto-immune disorders • Dual LSD1/HDAC6 inhibitors targeting cancer • Novel small molecule PD-L1 inhibitors • Novel brain penetrating PRMT5 inhibitors targeting cancer
keywords:N/AN/A
Total Funding
12
Number of Employees
$2.6M
Revenue (est)
-14%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.9M | 12 | -8% | N/A |
#2 | $2M | 18 | -5% | N/A |
#3 | $6.4M | 20 | -41% | N/A |
#4 | $1.8M | 23 | 0% | N/A |
#5 | $3.7M | 24 | 0% | N/A |